Effects of laser-weld joint opening size on fatigue strength of Ti-6Al-4V structures with several diameters

P>This study was conducted to evaluate the fatigue strength of Ti-6Al-4V laser-welded joints with several diameters and joint openings. Sixty dumbbell rods were machined in Ti-6Al-4V alloy with central diameters of 1 center dot 5, 2 center dot 0 and 3 center dot 5 mm. The specimens were sectioned and then welded using two joint openings (0 center dot 0 and 0 center dot 6 mm). The combination of variables created six groups, which when added to the intact groups made a total of nine groups (n = 10). Laser welding was executed as follows: 360 V per 8 ms (1 center dot 5 and 2 center dot 0 mm) and 380 V per 9 ms (3 center dot 5 mm) with focus and frequency regulated to zero. The joints were finished, polished and submitted to radiographic examination to be analysed visually for the presence of porosity. The specimens were then subjected to a mechanical cyclic test, and the number of cycles until failure was recorded. The fracture surface was examined with a scanning electron microscope (SEM). The Kruskal-Wallis test and Dunn test (alpha = 0 center dot 05) indicated that the number of cycles required for fracture was lower for all specimens with joint openings of 0 center dot 6 mm, and for 3 center dot 5-mm-diameter specimens with joint openings of 0 center dot 0 mm. The Spearman correlation coefficient (alpha = 0 center dot 05) indicated that there was a negative correlation between the number of cycles and the presence of porosity. So, laser welding of Ti-6Al-4V structures with a thin diameter provides the best conditions for the juxtaposition of parts. Radiographic examination allows for the detection of internal voids in titanium joints.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP

Fatigue strength: effect of welding type and joint design executed in Ti-6Al-4V structures

Fatigue strength: effect of welding type and joint design executed in Ti-6Al-4V structuresBackground: This study evaluated the fatigue strength of Ti-6Al-4V-machined structures submitted to laser (L)-welding and TIG (TIG)-welding procedures, varying the joint designs.Materials and methods: Seventy dumbbell rods were machined in Ti-6Al-4V alloy with central diameters of 3.5 mm. The specimens were sectioned and welded using TIG or L and three joint designs {'I' design, varying welding distances [0.0 mm (I00) or 0.6 mm (I06)], or 'X' [X] design}. The combinations of variables created six groups, which, when added to the intact group, made a total of seven groups (n = 10). L was executed as follows: 360 V/8 ms (X) and 390 V/9 ms (I00 and I06), with focus and frequency regulated to zero. TIG was executed using 2: 2 (X) and 3: 2 (I00 and I06) as welding parameters. Joints were finished, polished and submitted to radiographic examination to be analysed visually for the presence of porosity. The specimens were then subjected to mechanical cyclic tests, and the number of cycles completed until failure was recorded. The fracture surface was examined using a scanning electron microscope.Results: The Kruskal-Wallis and Dunn test (alpha = 0.05) indicated that the number of cycles resisted for fracture was higher to X for both welding procedures. To L, I06 was as resistant as X. The Mann-Whitney U-test (alpha = 0.05) indicated that L joints were more resistant than TIG to I00 and I06. Spearman's correlation coefficient (alpha = 0.05) indicated a negative correlation between the number of cycles and presence of porosity.Conclusion: Thus, to weld Ti-6Al-4V structures, the best condition is X, independent of the welding method employed.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP

Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib

Gastric cancer (GC) remains the third leading cause of cancer-related death despite several improvements in targeted therapy. There is therefore an urgent need to investigate new treatment strategies, including the identification of novel biomarkers for patient stratification. In this study, we evaluated the effect of FDA-approved kinase inhibitors on GC. Through a combination of cell growth, migration and invasion assays, we identified dasatinib as an efficient inhibitor of GC proliferation. Mass-spectrometry-based selectivity profiling and subsequent knockdown experiments identified members of the SRC family of kinases including SRC, FRK, LYN and YES, as well as other kinases such as DDR1, ABL2, SIK2, RIPK2, EPHA2, and EPHB2 as dasatinib targets. The expression levels of the identified kinases were investigated on RNA and protein level in 200 classified tumor samples from patients, who had undergone gastrectomy, but had received no treatment. Levels of FRK, DDR1 and SRC expression on both mRNA and protein level were significantly higher in metastatic patient samples regardless of the tumor stage, while expression levels of SIK2 correlated with tumor size. Collectively, our data suggest dasatinib for treatment of GC based on its unique property, inhibiting a small number of key kinases (SRC, FRK, DDR1 and SIK2), highly expressed in GC patients

ECPPA: Randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women

Objective To determine the effectiveness of low dose aspirin in women at high risk of adverse outcomes associated with pre-eclampsia.Design A collaborative randomised trial comparing the effects of low dose aspirin (60 mg) with placebo on pre-eclampsia and other materno-fetal complications associated with hypertension.Setting Twelve teaching maternity hospitals and 182 obstetricians' offices in Brazil.Subjects One thousand and nine women considered to be at high risk for the development of preeclampsia, or its complications, entered the study between 12 and 32 weeks of gestation. They were randomly allocated to receive aspirin (498 women) or placebo (511 women) until delivery, and follow up was obtained for 96%.Results There were no significant differences between the treatment groups in the incidence of proteinuric pre-eclampsia (6.7% aspirin-allocated compared with 6.0% placebo-allocated women), of preterm delivery (22.3% compared with 26.1%), of intrauterine growth retardation (8.5% compared with 10.1%), or of stillbirth and neonatal death (7.3% compared with 6.0%), nor were there significant differences in the incidence of proteinuric pre-eclampsia in any subgroup of women studied, including those who had systolic blood pressures of 120 mmHg or above at entry (8.5% compared with 7.3%) or those who were chronically hypertensive (10.0% compared with 7.1%). Aspirin was not associated with a significant excess of maternal or fetal bleeding.Conclusion The results of this study do not support the routine prophylactic administration of low dose aspirin in pregnancy to any category of high risk women (even those who have chronic hypertension or who are considered to be especially liable to early onset pre-eclampsia).ESCOLA PAULISTA MED,DEPT MED,MED CLIN D,RUA BOTUCATU 740,BR-04023900 SAO PAULO,BRAZILESCOLA PAULISTA MED,DEPT MED,MED CLIN D,RUA BOTUCATU 740,BR-04023900 SAO PAULO,BRAZILWeb of Scienc